In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1370-1374

  Zeckel, Michael L ^a   Preston, David A ^a   Allen, Bradley S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; DALFOPRISTIN PLUS QUINUPRISTIN; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG POTENCY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; VANCOMYCIN RESISTANCE;

EID: 0034050046     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1370-1374.2000     Document Type: Article

References (24)

1. Arthur, M., F. Depardieu, P. Reynolds, and P. Courvalin. 1999. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob. Agents Chemother. 43:1875-1880.
2. Biavasco, P., C. Vignaroli, R. Lupidi, E. Manso, B. Facinelli, and P. E. Varaldo. 1997. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41:2165-2172.
3. Caron, F., H. S. Gold, C. B. Wennersten, M. G. Farris, R. C. Moellering, and G. M. Eliopoulos. 1997. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 41:2749-2753.
4. Cormican, M. G., and R. N. Jones. 1996. Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs 51(Suppl. 1):6-12.
5. Fasola, E., S. K. Spangler, L. M. Ednie, M. R. Jacobs, S. Bajaksouzian, and P. C. Applebaum. 1996. Comparative activities of LY333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:2661-2663.
6. Fraise, A. P., J. Andrews, and R. Wise. 1997. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant Gram-positive organisms. J. Antimicrob. Chemother. 40:423-425.
7. Garcia-Garrote, F., E. Cercenado, L. Alcala, and E. Bouza. 1998. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. Antimicrob. Agents Chemother. 42:2452-2455.
8. Ge, M., Z. Chen, H. R. Onishi, J. Kohler, L. L. Silver, R. Kerns, S. Fukuzawa, C. Thompson, and D. Kahne. 1999. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-ala-D-ala. Science 284: 507-511.
9. Harland, S., S. E. Tebbs, and T. S. J. Elliott. 1998. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin. J. Antimicrob. Chemother. 41:273-276.
10. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
11. ®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 30:437-451.
12. Jones, R. N., C. H. Ballow, J. J. Schentag, D. M. Johnson, J. A. Deinhart, and the SPAR Study Group. 1998. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn. Microbiol. Infect. Dis. 31:313-325.
13. Jones, R. N., M. S. Barrett, and M. E. Erwin. 1996. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob. Agents Chemother. 41:488-493.
14. Jones, R. N., D. E. Low, and M. A. Pfaller. 1999. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. 33:101-112.
15. Kaplan, S. L., and E. O. Mason. 1998. Management of infections due to antibiotic resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11:628-644.
16. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. M100-S9. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Nicas, T. I., D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, M. J. Zweifel, S. C. Wilkie, M. J. Rodriguez, R. C. Thompson, and R. D. G. Cooper. 1996. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 40:2194-2199.
19. Patel, R., M. S. Rouse, K. E. Piper, F. R. Cockerill, and J. M. Steckelberg. 1998. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 30:89-92.
20. Saleh-Mghir, A., A. Lefort, Y. Petegnief, S. Dautrey, J. Vallois, D. Le Guludec, C. Carbon, and B. Fantin. 1999. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 43:115-120.
21. Schwalbe, R. S., A. C. McIntosh, S. Qaiyumi, J. A. Johnson, R. J. Johnson, K. M. Furness, W. J. Holloway, and L. Steele-Moore. 1996. In vitro activity of the LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob. Agents Chemother. 40:2416-2419.
22. Schwalbe, R. S., J. T. Stapleton, and P. H. Gilligan. 1987. Emergence of vancomycin resistant coagulase-negative staphylococci. N. Engl. J. Med. 316: 927-931.
23. Wenzel, R. P. 1985. Surveillance, p. 1604-1608. In G. L. Mandell, R. G. Douglas, and J. E. Bennett (ed.), Principles and practice of infectious diseases, 2nd ed. John Wiley and Sons, Inc., New York, N.Y.
24. Woodford, N., A. P. Johnson, D. Morrison, and D. C. E. Speller. 1995. Current perspectives on glycopeptide resistance. Clin. Microbiol. Rev. 8:585-615.